We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

38 hedge funds and large institutions have $4.58M invested in Oncternal Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more capital invested

Capital invested by funds: $2.81M → $4.58M (+$1.77M)

24% less funds holding

Funds holding: 50 → 38 (-12)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

79% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 14

Holders
38
Holders Change
-12
Holders Change %
-24%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
8
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$147K
2
PPW
Pasadena Private Wealth
California
+$79.7K
3
Morgan Stanley
Morgan Stanley
New York
+$31.7K
4
Citadel Advisors
Citadel Advisors
Florida
+$19.5K
5
TSS
Two Sigma Securities
New York
+$13.5K

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$144K
2
QPW
Quantum Private Wealth
Florida
-$138K
3
BJL
Brighton Jones LLC
Washington
-$102K
4
Corient Private Wealth
Corient Private Wealth
Florida
-$27.5K
5
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$16.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.53M – – –
Millennium Management
2
Millennium Management
New York
$1.1M +$147K +20,433 +25%
BlackRock
3
BlackRock
New York
$421K – – –
PPW
4
Pasadena Private Wealth
California
$268K +$79.7K +11,062 +79%
RB
5
Richmond Brothers
Michigan
$265K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$175K +$5.01K +695 +4%
Morgan Stanley
7
Morgan Stanley
New York
$99.7K +$31.7K +4,399 +90%
LPL Financial
8
LPL Financial
California
$91.9K – – –
State Street
9
State Street
Massachusetts
$86.5K – – –
IC
10
IEQ Capital
California
$77.4K – – –
Northern Trust
11
Northern Trust
Illinois
$45.4K – – –
Two Sigma Advisers
12
Two Sigma Advisers
New York
$44.8K -$5.33K -740 -15%
Two Sigma Investments
13
Two Sigma Investments
New York
$40K – – –
Acadian Asset Management
14
Acadian Asset Management
Massachusetts
$38K – – –
AWM
15
Axxcess Wealth Management
California
$37.7K – – –
TSS
16
Two Sigma Securities
New York
$31.5K +$13.5K +1,877 +177%
Citadel Advisors
17
Citadel Advisors
Florida
$29.1K +$19.5K +2,714 New
ROTUOC
18
Regents of the University of California
California
$28.7K – – –
BWP
19
Balboa Wealth Partners
Arizona
$25.5K – – –
Creative Planning
20
Creative Planning
Kansas
$21.1K – – –
Charles Schwab
21
Charles Schwab
California
$17.3K – – –
BWG
22
Beta Wealth Group
California
$17.2K – – –
AAM
23
Aureus Asset Management
Massachusetts
$16.2K – – –
VFA
24
Valeo Financial Advisors
Indiana
$12.6K -$3.96K -550 -32%
IIA
25
IPG Investment Advisors
California
$12.5K +$8.4K +1,166 New
1
2 3

ONCT Hedge Fund Activity: Q4 2023 in Review

38 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2023, worth a combined $4.58M — up 63% from $2.81M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of ONCT and 3 opened new positions — a net loss of 11 holders — while 8 trimmed existing stakes and 6 added.

The largest buyer was Millennium Management, adding an estimated $147K. The largest seller was Geode Capital Management, exiting entirely with an estimated $144K sold.

  • 38 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2023, down from 50 in Q3 2023.
  • Funds reported $4.58M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2023, up 63% quarter-over-quarter.
  • 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2023 and 14 closed out, a net change of -11 holders.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2023 was Millennium Management, an estimated $147K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2023 was Geode Capital Management, an estimated $144K sold.

Based on aggregated 13F filings for Q4 2023.